Author's posts
This Is A Heart Drug That The World Doesn’t Need
So what we have here is a drug whose window of opportunity has been closed.
Covid-19 Vaccine Pricing Will Impact Big Pharma’s Reputation
If Big Pharma isn’t profitable, it won’t survive. We’ll need to remember that when the next pandemic hits.
Will Moderna Match Competitors’ Covid-19 Vaccine Prices?
Can smaller companies like Moderna be able to compete commercially in such an environment given the expectations of investors?
Large R&D Investments By Big Pharma Crucial In Fighting Covid-19, But Can It Last?
One good thing that has come out of the current coronavirus pandemic is that the public is getting a big lesson in the trials and tribulations of drug discovery and development.
Fate Of Pharma’s Reputation Lies In Gilead’s Hands On Pricing Of Covid-19 Drug Remdesivir
Gilead’s decision will set the tone for the Covid-19 vaccines and drugs that will follow. It will also impact the reputation of the whole industry. It’s not an easy decision. Let’s hope they get it right.
Contrary To The Views Of Naysayers, Covid-19 Pandemic Is Showing The Importance Of Biopharma
If anything, the coronavirus pandemic shows that the biopharmaceutical industry is vibrant and can be very responsive to pandemics. Is it perfect? No. But, we should all be thankful we have it in times like these.
Remdesivir Approved For COVID-19 – Let The Gilead Attacks Begin
Finally, please recognize that biopharma is our best hope in getting past this pandemic.
Human Insulin Is Available For As Little As $24.88 – But It’s Not For Everyone
Human insulin is different from synthetic insulin, and one is significantly cheaper.
Who Are The Scofflaws On Reporting Clinical Data? Surprisingly, Not Big Pharma.
But the fact of the matter is that this lack of attention to important reporting requirements is hurting patients who bravely volunteer for these studies.
The Conundrum Of Investing In Cardiovascular Versus Rare Diseases R&D
It’s important to recognize that an R&D organization must use its resources to maximize the return on a company’s investment. To do that, investments must be made in therapeutic areas where the odds of technical, regulatory and commercial success are h…
